SYNALAR-HP

LOE Approaching

fluocinolone acetonide

NDATOPICALCREAM
Approved
Jul 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16

Clinical Trials (5)

NCT05844982Phase 3Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Started Nov 2023
600 enrolled
Radiation RetinopathyVisual Impairment
NCT05322070Phase 4Active Not Recruiting

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Started Jun 2022
125 enrolled
Uveitis, Posterior
NCT03145025N/ACompleted

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Started Jul 2017
3 enrolled
Uveitis, Posterior
NCT01060787N/ACompleted

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

Started Feb 2016
98 enrolled
InflammationUveitis
NCT01304706Phase 3Completed

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

Started Apr 2011
120 enrolled
Diabetic Macular Edema
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.